Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Summary

Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research study is evaluating a new blood test that is capable of detecting an EGFR mutation in cancer without a biopsy.

Timeline

Start

2016-06

Primary completion

2019-04-16

Completion

2019-06-19

Outcome

Outcome not reported

Stopped: “Terminated due to Osimertinib approval”

Drugs

Indications